Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lantern Pharma ( (LTRN) ) has issued an announcement.
On April 9, 2026, Lantern Pharma Inc. conducted a live demonstration of its withZeta.ai platform, showcasing the multi-agentic AI co-scientist’s capabilities in rare cancer drug discovery, development and clinical trial design. The presentation detailed the platform’s commercial architecture, rare cancer market opportunity, competitive positioning and the company’s near-term revenue strategy and growth roadmap tied to the rollout of withZeta.ai.
The event underscored Lantern’s bid to carve out a competitive position in the emerging market for AI-enabled oncology R&D tools, with management highlighting software licensing and subscription models as future revenue drivers. However, the company also flagged substantial risks, including funding needs, uncertainty around research success, the possibility that partnerships may not materialize and the chance that commercialization efforts for withZeta.ai may fall short of anticipated revenue and market adoption.
The most recent analyst rating on (LTRN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Lantern Pharma stock, see the LTRN Stock Forecast page.
Spark’s Take on LTRN Stock
According to Spark, TipRanks’ AI Analyst, LTRN is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and material cash burn implying future financing risk) and bearish technicals (price below key moving averages with negative momentum). Positive clinical milestones and AI platform progress from the earnings call provide support, but are outweighed by near-term funding needs and the lack of earnings-based valuation support.
To see Spark’s full report on LTRN stock, click here.
More about Lantern Pharma
Lantern Pharma Inc. is a biopharmaceutical company focused on oncology, leveraging artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of cancer drug discovery and development. The company is increasingly emphasizing AI-driven platforms, including its withZeta.ai multi-agentic AI co-scientist, to target rare cancer indications and optimize clinical trial design.
Average Trading Volume: 533,428
Technical Sentiment Signal: Sell
Current Market Cap: $21.05M
For an in-depth examination of LTRN stock, go to TipRanks’ Overview page.